Target Name: LYPD3
NCBI ID: G27076
Other Name(s): LY6/PLAUR domain containing 3 | GPI-anchored metastasis-associated protein C4.4A homolog | LYPD3_HUMAN | Matrigel-induced gene C4 protein | GPI-anchored metastasis-associated protein homolog | matrigel-induced gene C4 protein | Ly6/PLAUR domain-containing protein 3 | MIG-C4 | 2310061G07Rik | C4.4A

LYPD3: A Potential Drug Target for Muscle Contraction, Cell Signaling and Tissue Repair

The LYPD3 protein is a cytoskeletal protein that is expressed in various tissues of the body, including muscle, bone, and heart. It is a key component of the actin filament, which is a protein structure that plays a crucial role in the mechanical properties of cells. The LYPD3 protein has been identified as a potential drug target and has been shown to be involved in a variety of cellular processes, including muscle contraction, cell signaling, and tissue repair.

LYPD3 function and structure

The LYPD3 protein is a 21-kDa protein that consists of 158 amino acid residues. It has a unique structure that is composed of a domain containing the cytoskeletal protein LY6 and a domain containing the protein PLAUR. The LY6 domain is responsible for the protein's cytoskeletal functions, while the PLAUR domain is involved in the regulation of actin dynamics and cell signaling.

The LYPD3 protein has a unique cytoskeletal structure that is composed of a series of parallel beta-strands that are connected by various non-尾 hydrogen bonds. The protein's cytoskeletal structure gives it a unique 3D structure that is involved in the regulation of actin dynamics and the mechanical properties of cells.

LYPD3 function

The LYPD3 protein is involved in a variety of cellular processes, including muscle contraction, cell signaling, and tissue repair. One of the most well-studied functions of LYPD3 is its role in muscle contraction. LYPD3 is expressed in muscle cells and is involved in the regulation of muscle cell contractions.

Several studies have shown that LYPD3 plays a key role in the regulation of muscle cell contractions. For example, one study published in the journal Cell Research found that LYPD3 was involved in the regulation of muscle cell contractions in mice. The authors found that LYPD3 was expressed in muscle cells and was involved in the regulation of muscle cell contractions.

LYPD3 is also involved in the regulation of cell signaling, particularly in the regulation of T cell signaling. Several studies have shown that LYPD3 is involved in the regulation of T cell signaling in the immune system. For example, one study published in the journal Molecular Therapy found that LYPD3 was involved in the regulation of T cell signaling in the immune response.

LYPD3 is also involved in the regulation of tissue repair. The LYPD3 protein has been shown to be involved in the regulation of tissue repair in the liver. For example, one study published in the journal liver Research found that LYPD3 was involved in the regulation of liver tissue repair in rats. The authors found that LYPD3 was expressed in rat liver tissue and was involved in the regulation of liver tissue repair.

Drug targeting LYPD3

The LYPD3 protein is a potential drug target because of its unique structure and function. Several studies have shown that LYPD3 is involved in a variety of cellular processes, including muscle contraction, cell signaling, and tissue repair. As a result, LYPD3 has been identified as a potential drug target for a variety of diseases.

One of the most promising approaches to targeting LYPD3 is the use of small molecules. Several studies have shown that LYPD3 is sensitive to small molecules, such as inhibitors and activators. For example, one study published in the journal Biochimica et Biophysica Acta found that an Inhibitor of LYPD3 was shown to be effective in inhibiting muscle contractions in mice.

Another approach to targeting LYPD3 is the use of antibodies. Several studies have shown that LYPD3 is

Protein Name: LY6/PLAUR Domain Containing 3

Functions: Supports cell migration. May be involved in urothelial cell-matrix interactions. May be involved in tumor progression

More Common Targets

LYPD4 | LYPD5 | LYPD6 | LYPD6B | LYPD8 | LYPLA1 | LYPLA2 | LYPLA2P1 | LYPLA2P2 | LYPLAL1 | LYPLAL1-AS1 | LYRM1 | LYRM2 | LYRM4 | LYRM4-AS1 | LYRM7 | LYRM9 | LYSET | Lysine-Specific Demethylase 3 | Lysine-specific demethylase 5 | LYSMD1 | LYSMD2 | LYSMD3 | LYSMD4 | Lysophospholipid (edg) Receptors | LYST | Lysyl Oxidase Homolog | LYVE1 | LYZ | LYZL1 | LYZL2 | LYZL4 | LYZL6 | LZIC | LZTFL1 | LZTR1 | LZTS1 | LZTS1-AS1 | LZTS2 | LZTS3 | m-Calpain | M1AP | M6PR | MAB21L1 | MAB21L2 | MAB21L3 | MAB21L4 | MACC1 | MACC1-DT | MACF1 | MACIR | MACO1 | MACORIS | MACROD1 | MACROD2 | MACROD2-AS1 | MACROH2A1 | MACROH2A2 | MAD1L1 | MAD2L1 | MAD2L1BP | MAD2L2 | MADCAM1 | MADD | MAEA | MAEL | MAF | MAF1 | MAFA | MAFA-AS1 | MAFB | MAFF | MAFG | MAFIP | MAFK | MAFTRR | MAG | MAGEA1 | MAGEA10 | MAGEA11 | MAGEA12 | MAGEA13P | MAGEA2 | MAGEA2B | MAGEA3 | MAGEA4 | MAGEA5P | MAGEA6 | MAGEA7P | MAGEA8 | MAGEA9 | MAGEA9B | MAGEB1 | MAGEB10 | MAGEB16 | MAGEB17 | MAGEB18 | MAGEB2 | MAGEB3 | MAGEB4